Loading clinical trials...

Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF). | Clinical Trials | Clareo Health

COMPLETEDNA

Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).

NCT01946360•Institute of Liver and Biliary Sciences, India

View on ClinicalTrials.gov

Summary

Blood will be collected after venepuncture from all patients for complete blood counts, Serum bilirubin (direct and indirect), aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, prothrombin time and INR, urea, creatinine, sodium, potassium, serum total protein and albumin, within 24 hours after admission and twice a week there after or as and when needed. Time line for blood tests and evaluation of clinical parameters \& 13C-MBT For ALF patients: On days 0, 1, 3, and 7 For ACLF patients: On days 0, 7 (week 1), 14(week 2), 28 (weeks 4) Blood tests would include: Serum bilirubin (total and direct), aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyltransferase, Serum proteins (total and albumin), prothrombin time \& international normalized ratio (INR), Serum urea and creatinine, serum electrolytes, arterial ammonia and arterial blood gas analysis.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- All patients presenting with acute liver failure and acute on chronic liver failure (between 18 - 70 years of age) to Institute of Liver \& Biliary Sciences (ILBS), New Delhi, India.

Exclusion Criteria

•1. Patients with significant co-morbid illnesses such as cardiovascular or respiratory or intrinsic renal diseases which by themselves may have a bearing on the outcome.
•2. Patients with previous intestinal bypass surgery for morbid obesity
•3. Patients with extensive small bowel resection
•4. Patients currently receiving total parenteral nutrition
•5. Pregnant women
•6. Patients with history of allergy to paracetamol
•7. Patients on steroids or anti-fungal agents
•8. Patients in encephalopathy
•9. Patients unwilling to participate in the protocol
•10. Patients on medications which can alter the activity of CYP 1A2 enzymes such as corticosteroids, amiodarone, tetracycline, niacin, valproic acid, methotrexate, stavudine and zidovudine.

Locations (1)

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, India

Key Dates

Start Date

April 1, 2014

Primary Completion Date

January 1, 2015

Completion Date

January 1, 2015

Last Updated

September 29, 2015

Enrollment

ACTUAL participants

Conditions

Acute Liver FailureAcute on Chronic Liver Failure

Interventions

Methacetin Breath Test in ACLF and ALF patients

DEVICE

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

NCT07329036

Acute Liver Failure

View study

RECRUITINGNA

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

NCT06831643

Acute Liver Failure

View study

RECRUITING

Study About Hepatic Toxins Kinetic and Evaluation of Organ Damage in Acute on Chronic Liver Failure (ACLF) Patients

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).

Inclusion Criteria

Exclusion Criteria

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

Study About Hepatic Toxins Kinetic and Evaluation of Organ Damage in Acute on Chronic Liver Failure (ACLF) Patients

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Safety and Tolerability of Hepatocyte-like Cell Therapy for Liver Failure and Small-for-Size Syndrome